A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure.
Phase of Trial: Phase I/II
Latest Information Update: 07 Jul 2016
At a glance
- Drugs CXL 1020 (Primary)
- Indications Chronic heart failure; Heart failure
- Focus Adverse reactions; Biomarker
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 06 Apr 2011 Results were presented at the Annual Meeting of the American College of Cardiology (ACC-2011).
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History